BACKGROUND: Chromosome 17 abnormalities are associated with poor outcome in leukemias including AML. Recently, MK was introduced as an independent predictor of dismal outcome in AML. The additional prognostic effect of C17 abns in patients with MK in a CK background is not clear. PATIENTS AND METHODS: We conducted a retrospective analysis of 1086 patients with newly diagnosed AML treated between January 1998 and December 2007. Patients received treatment with one of the institution's first-line protocols. RESULTS: Four hundred eighty-three patients had CK. Among them, 370 patients (77%) had CK-MK, and 195 patients (53%) had CK-MK-C17 abns. Patients with CK-MK had significantly shorter OS rates compared with patients with CK without MK (4.4 vs. 8 months, respectively; P = .002). The median OS for patients with CK-C17 abns was shorter than for patients without C17 abns (4 vs. 6.1 months, respectively; P = .004). In a multivariate analysis, the presence of MK among patients with CK was identified as an independent prognostic marker for OS. In addition, presence of C17 abns had a significant negative effect on OS among patients with CK-MK (P = .04). CONCLUSION: Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML.
BACKGROUND: Chromosome 17 abnormalities are associated with poor outcome in leukemias including AML. Recently, MK was introduced as an independent predictor of dismal outcome in AML. The additional prognostic effect of C17abns in patients with MK in a CK background is not clear. PATIENTS AND METHODS: We conducted a retrospective analysis of 1086 patients with newly diagnosed AML treated between January 1998 and December 2007. Patients received treatment with one of the institution's first-line protocols. RESULTS: Four hundred eighty-three patients had CK. Among them, 370 patients (77%) had CK-MK, and 195 patients (53%) had CK-MK-C17abns. Patients with CK-MK had significantly shorter OS rates compared with patients with CK without MK (4.4 vs. 8 months, respectively; P = .002). The median OS for patients with CK-C17abns was shorter than for patients without C17abns (4 vs. 6.1 months, respectively; P = .004). In a multivariate analysis, the presence of MK among patients with CK was identified as an independent prognostic marker for OS. In addition, presence of C17abns had a significant negative effect on OS among patients with CK-MK (P = .04). CONCLUSION: Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17abns further worsens the outcome in these particularly poor-risk patients with AML.
Authors: G Visani; P Bernasconi; M Boni; G L Castoldi; S Ciolli; M Clavio; M C Cox; A Cuneo; G Del Poeta; D Dini; D Falzetti; R Fanin; M Gobbi; A Isidori; F Leoni; V Liso; M Malagola; G Martinelli; C Mecucci; P P Piccaluga; M C Petti; R Rondelli; D Russo; M Sessarego; G Specchia; N Testoni; G Torelli; F Mandelli; S Tura Journal: Leukemia Date: 2001-06 Impact factor: 11.528
Authors: P Fenaux; C Preudhomme; I Quiquandon; P Jonveaux; J L Laï; M Vanrumbeke; M H Loucheux-Lefebvre; F Bauters; R Berger; J P Kerckaert Journal: Br J Haematol Date: 1992-02 Impact factor: 6.998
Authors: J Drach; J Ackermann; E Fritz; E Krömer; R Schuster; H Gisslinger; M DeSantis; N Zojer; M Fiegl; S Roka; J Schuster; R Heinz; H Ludwig; H Huber Journal: Blood Date: 1998-08-01 Impact factor: 22.113
Authors: Fan Zhou; Fen Zhou; Mengyi Du; Lin Liu; Tao Guo; Linghui Xia; Runming Jin; Yu Hu; Heng Mei Journal: Int J Hematol Date: 2019-08-22 Impact factor: 2.490
Authors: Stephen A Strickland; Zhuoxin Sun; Rhett P Ketterling; Athena M Cherry; Larry D Cripe; Gordon Dewald; Hugo F Fernandez; Gary A Hicks; Rodney R Higgins; Hillard M Lazarus; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Jacob M Rowe; Gail H Vance; Peter Wiernik; Anne E Wiktor; Yanming Zhang; Martin S Tallman Journal: Leuk Res Date: 2017-05-12 Impact factor: 3.156
Authors: Marcelo C Pasquini; Mei-Jie Zhang; Bruno C Medeiros; Philippe Armand; Zhen-Huan Hu; Taiga Nishihori; Mahmoud D Aljurf; Görgün Akpek; Jean-Yves Cahn; Mitchell S Cairo; Jan Cerny; Edward A Copelan; Abhinav Deol; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Biju George; Vikas Gupta; Gregory A Hale; Rammurti T Kamble; Thomas R Klumpp; Hillard M Lazarus; Selina M Luger; Jane L Liesveld; Mark R Litzow; David I Marks; Rodrigo Martino; Maxim Norkin; Richard F Olsson; Betul Oran; Attaphol Pawarode; Michael A Pulsipher; Muthalagu Ramanathan; Ran Reshef; Ayman A Saad; Wael Saber; Bipin N Savani; Harry C Schouten; Olle Ringdén; Martin S Tallman; Geoffrey L Uy; William A Wood; Baldeep Wirk; Waleska S Pérez; Minoo Batiwalla; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2015-08-29 Impact factor: 5.742
Authors: Heiko Becker; Dietmar Pfeifer; Gabriele Ihorst; Milena Pantic; Julius Wehrle; Björn H Rüter; Lars Bullinger; Björn Hackanson; Ulrich Germing; Andrea Kuendgen; Uwe Platzbecker; Konstanze Döhner; Arnold Ganser; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner; Justus Duyster; Michael Lübbert Journal: Ann Hematol Date: 2020-06-06 Impact factor: 3.673
Authors: Hartmut Döhner; Anna Dolnik; Lin Tang; John F Seymour; Mark D Minden; Richard M Stone; Teresa Bernal Del Castillo; Haifa Kathrin Al-Ali; Valeria Santini; Paresh Vyas; C L Beach; Kyle J MacBeth; Barry S Skikne; Steve Songer; Nora Tu; Lars Bullinger; Hervé Dombret Journal: Leukemia Date: 2018-10-01 Impact factor: 11.528